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ABSTRACT
Data on antiretroviral drug resistance among drug-naïve persons are important in developing sentinel 
surveillance policies. This study was conducted to determine the prevalence of antiretroviral drug resis-
tance mutations among drug-naïve HIV-infected individuals attending a voluntary testing and counselling 
centre at the Mankweng Hospital in northeastern South Africa. In total, 79 drug-naïve HIV-positive indi-
viduals were sequentially recruited during February 2008–December 2008. Drug resistance mutations were 
determined using the calibrated population resistance tool available on the Stanford HIV drug resistance 
database. Viral DNA was obtained from 57 (72%) of the 79 individuals. Reliable nucleotide sequences were 
obtained for 54 reverse transcriptase (RT) and 54 protease (PR) gene regions from 54 individuals. Overall, 
five sequences (9.3%) harboured drug resistance mutations (95% confidence interval -1.53 to 16.99). Four 
(7.4%) of these were nucleoside RT inhibitor mutations (D67G, D67E, T69D, and T215Y), and one (1.9%) 
was a PR inhibitor mutation (M46I). No major non-nucleoside RT resistance mutation was detected. Sev-
eral minor resistance mutations and polymorphisms common in subtype C viruses were observed in the 
PR and RT genes. Phylogenetic analysis of the partial pol sequences showed that 52 (96%) of the 54 isolates 
were HIV-1 subtype C. One isolate (08MB08ZA) was HIV-1 subtype B while another (08MB26ZA) was relat-
ed to HIV-1 subtype J. HIV-1 subtype recombination analysis with REGA assigned the pol sequence to HIV 
subtype J (11_cpx) with a bootstrap value of 75%. The prevalence of drug resistance mutations observed in 
the population studied was relatively higher than previously reported from other parts of South Africa. In 
addition, this is apparently the first report of an HIV-1 subtype J-like virus from northeastern South Africa.
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INTRODUCTION
The health and quality of life of patients infected 
with HIV/AIDS have dramatically improved since 
the introduction of highly-active antiretroviral 
therapy (HAART) in 1996 (1,2). However, one of 
the major drawbacks of HAART is the development 
of drug resistance which usually accompanies the 
use of antiretrovirals (ARVs) (2,3). Drug-naïve indi-
viduals with ARV drug resistance have a relatively 
higher risk of virologic failure as they start antiret-
roviral treatment (ART) with a lower genetic barrier 
to resistance (4). In addition, harbouring resistance 
viruses before the initiation of treatment compli-
cates alternative treatment algorithms.
In the developed world, HAART has been used with 
remarkable success, and treatment is accompanied 
with regular virologic monitoring, including meas-
urements of viral load and testing of drug resistance 
to guide management of patients (5,6). On the oth-
er hand, the use of HAART in resource-poor settings 
still poses a lot of problems. Virological monitoring 
is less frequently done due to involvement of cost 
and dearth of qualified personnel. Nwobegahay JM et al. Antiretroviral drug resistance among drug-naïve persons
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South Africa has one of the highest HIV/AIDS preva- 
lence in the world, and the South African National 
HIV and Syphilis Survey in 2007 showed that the 
estimated prevalence was 28% (7), with the Lim-
popo province (northeastern South Africa) having a 
prevalence of 20.7%. Before 2004, ARVs were avail-
able only through private health establishments in 
South Africa, and due to the scarcity and prohibitive 
high cost, the majority of patients could not afford 
treatment. In early 2004, a national ARV delivery 
programme was initiated to provide drugs to those 
who had a CD4 count of <200 cells/μL or with a 
clinically-defined AIDS condition. Before 2010, the 
South African ARV drug regimen guideline recom-
mended the use of stavudine, lamivudine, and 
efavirenz (with nevirapine replacing efavirenz for 
women of childbearing age). Currently, the revised 
regimen comprises tenofovir, lamivudine, and efa-
virenz/nevirapine. Stavudine is still recommended 
where side-effects are tolerated (8).
The determination of a regimen based on the ge-
netic resistance profiles of patients’ viruses before 
the initiation of therapy generally correlates with 
a better outcome compared to the absence of such 
resistance data (3,9). Information on the presence 
of resistant viruses is important in tailoring combi-
nation regimens or to decide whether to prescribe 
testing of resistance before the initiation of therapy. 
It was estimated that 500,000 adults and children 
were receiving ARVs in South Africa by mid-2008, 
with about 34,000 of them in Limpopo province 
(northern South Africa) (10). In South Africa, 
some studies have indicated the prevalence of ge-
netic drug resistance among the naïve population 
of less than 5% (9,11). However, despite the low 
prevalence reported, it is important to monitor the 
prevalence of drug resistance in drug-naïve popula-
tions, particularly in regions, such as northeast of 
South Africa where such data are scarce. The only 
data on resistance available for northern South Af-
rica were obtained from samples collected in 2001 
from Waterberg district (10,12) before the avail-
ability of ARVs through the public health sector in 
2004. Findings of these studies showed the absence 
of resistance mutations in the samples studied. In 
addition, since 2004, access to ARVs has escalated 
in northern South Africa (from an estimated 300 in 
2001 to 34,000 in 2008) (11), and it is important 
to address development of drug resistance through 
periodic studies. The aim of this study was, there-
fore, to provide baseline data on ARV drug resist-
ance mutations in Mankweng (Capricorn district), 
one of the areas where ART first began in northeast-
ern South Africa in 2004 and where no resistance 
data are available. Information generated could be 
useful in developing sentinel surveillance policies 
for the region.
MATERIALS AND METHODS
Study population, sample collection, and 
plasma preparation
Individuals without prior exposure to ARVs and 
who tested positive for HIV antibodies at the HIV 
Voluntary Testing and Counselling Centre at the 
Mankweng Hospital, South Africa, were recruited 
sequentially during February 2008–December 
2008. Viral load and CD cell counts are not rou-
tinely measured at the clinic, and data on these 
were not available. Participants were apparently 
healthy individuals at the time of HIV testing. The 
Mankweng Hospital is a component of the Polok-
wane-Mankweng Hospital Complex, a regional re-
ferral hospital for Limpopo province in northern 
South Africa. The Voluntary Testing and Counsel-
ling Centre at the Mankweng Hospital caters to 19 
health centres in the rural precincts of Mankweng.
Five mL of venous blood was collected into an 
EDTA vacutainer tube from each consenting sub-
ject. A questionnaire was used for collecting demo-
graphic data, such as age, sex, place of residence, 
probable date and place of infection, and marital 
status. Most (87.3%) samples were processed for to-
tal RNA extraction within 48 hours while stored at 
4 °C. However, 10 samples, due to transportation 
logistics, were stored at 4 °C for four days before 
RNA isolation. Whole blood was spun at 3,000 rpm 
for three minutes. Plasma was aspirated aseptically 
and stored at -80 ˚C for subsequent RNA extraction. 
Data on viral load and CD4 count were not avail-
able.
Isolation of viral RNA, RT-PCR, and nested PCR
Viral RNA was isolated using the viral mini RNA kit 
(Qiagen, Hilden, Germany) and stored at -80 °C un-
til used. Two protocols were used at different times 
for amplifying the HIV polymerase gene. In one 
protocol, a one-tube RT-polymerase chain reaction 
(RT-PCR) was performed with AMV RT (Roche, USA) 
and Taq DNA polymerase (Invitrogen), followed by 
a nested PCR as previously described (10). This gene- 
rated approximately a 1.4-kb product comprising 
the entire PR and at least 900 bp of the RT gene. 
In the other protocol, cDNA was synthesized us-
ing the Thermoscript RT-PCR system (Invitrogen, 
Hilden, Germany). Thereafter, a 1.7-kb fragment of 
the polymerase gene comprising the entire PR and 
at least 1200 bp of the RT gene was amplified us-
ing the Expand Long Template System (Roche) as 
previously described (11). The PCR products were 
verified for expected size by electrophoresis of 1% 
agarose gel stained with ethidium bromide. PCR 
amplicons were purified with QIAquick PCR puri-Nwobegahay JM et al.
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fication kit (Qiagen, Hilden, Germany), and direct 
population-based sequencing was performed on 
both strands with the BigDye Terminator v3.0 kit 
on ABI Prism 377 (Applied Biosystems) using Taq 
DNA polymerase. Generated nucleotide sequences 
were edited manually using the SeqMan II software 
(version 7) (DNASTAR, Lasergene, USA).
Viral genetic subtyping 
Subtyping of HIV was done by phylogenetic analy-
sis. Polymerase sequences (880 bp) comprising the 
complete PR and partial RT genes of test viruses 
were aligned using ClustalX with representative 
subtype reference sequences (group M subtypes A-
D, F-H, J, and K, excluding recombinant sequences) 
obtained from GenBank (13). Previously-described 
sequences from Limpopo province were included 
in analysis. Neighbour-joining phylogenetic trees 
were generated with the PHYLIP programme, mak-
ing the use of the maximum likelihood model to 
take care of differences in the transition and trans-
version rates. Trees were rooted with an HIV-1 
group O strain (L20571). The reliability of the trees 
was assessed by a bootstrapping of 1,000 replicates. 
REGA HIV-1 and 2 subtyping tool (version 2.0) was 
used for analyzing the sequences for recombina-
tion (14,15). The tool employs phylogenetic anal-
ysis and bootscanning methods to assign genetic 
subtypes. Predicted amino acids of the PR and RT 
genes were aligned using the BioEdit program (16). 
Consensus amino acid sequences of the PR and RT 
regions were created and then compared with the 
global subtype C and the global subtype B consen-
sus sequences obtained from GenBank (2000). The 
mean genetic distances among the PR and RT se-
quences were determined by the Kimura 2- param-
eter model.
Determination of genetic drug resistance 
Drug resistance mutations were examined accord-
ing to the calibrated population resistance (CPR) 
tool (version 5.0) beta contained in the Stanford 
HIV Drug Resistance database (http://cpr.stanford.
edu/cpr/servlet/CPR). The CPR tool analyzes sub-
mitted sequences for resistance mutations based 
on the surveillance transmitted drug resistance 
mutations list of the World Health Organization 
(17). The tool also detects unusual, bad and hyper 
mutated sequences and performs assignment of 
subtype. 
Ethical considerations
The Health, Safety, and Research Ethics Committee 
of the University of Venda, South Africa, approved 
the study protocol. The Limpopo Provincial De-
partment of Health and the Mankweng Hospital 
permitted to conduct the study. Signed informed 
consent was obtained from each study participant. 
RESULTS
Demographics of study subjects
In total, 79 HIV-positive individuals were sequen-
tially recruited for the study. Their mean age was 
38.5 (range 18-59) years. The proportion of women 
and men was 73.4% and 25% respectively. About 
80% of the study subjects were single, and 22.8% 
were married. The most important risk factor for 
HIV transmission based on responses to the ques-
tionnaire was sexual intercourse (97.5%). However, 
the questionnaire was not designed to determine 
whether it was heterosexual or homosexual. In 
89.9% of the participants, the most probable place 
of HIV infection was South Africa. About 47% of 
the subjects were infected in 2008 while the re-
maining subjects estimated that they were infected 
during 2000-2007. The highest level of education 
for 79.7% of the participants was grade 6 and above 
but no university graduates were recorded within 
the participants. Details of the demographic and 
socioeconomic characteristics of the study popula-
tion are shown in the Table.
Viral DNA amplification drug resistance 
mutations
Viral DNA was obtained for 57 (72%) of the 79 in-
dividuals. Reliable nucleotide sequences were ob-
tained for 54 RT genes and 54 PR genes, on which 
genetic subtyping and drug resistance mutation 
analyses were done. Using the CRP analysis for sur-
veillance drug resistance mutations, five (9.3%) of 
the 54 sequences had mutations associated with 
drug resistance (95% confidence interval -1.53 to 
16.99). These included four NRTI mutations 
(D67E, D67G, T69D, and T215Y) harboured by se-
quences 08MB38ZA, 08MB26ZA, 08MB27ZA, and 
08MB29ZA respectively, and one PI resistance mu-
tation (M46I) observed in sequence 08MB62ZA. No 
NNRTI mutation was detected, and no sequence 
harboured more than one resistance mutation. 
HIV genetic subtypes
Phylogenetic analysis of the partial pol sequences 
showed that 52 (96.3%) of the 54 isolates were HIV-1 
subtype C. One isolate (08MB08ZA) was HIV-1 sub-
type B while isolate 08MB26ZA was observed to be 
related to HIV-1 subtype J reference sequences (Fig. 
1). Bootscanning analysis of 08MB26ZA with the 
REGA HIV-1 subtyping tool showed that its pol gene Nwobegahay JM et al. Antiretroviral drug resistance among drug-naïve persons
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Table. Demographic and socioeconomic char-
acteristics of study population
Characteristics
Patients (n=79)
No. %
Sex 
   Male 20 25.3
   Female 58 73.4
   Data not available 01 1.3
Marital status
   Single 56 70.9
   Married 18 22.8
   Widowed 01 1.3
   Divorced 02 2.5
   Data not available 02 2.5
Probable place of infection
   South Africa 71 89.9
   Other countries 00 0
   Data not available 8 10.1
Risk factor for transmission
   Sex 77 97.5
   Data not available 02  2.5
Probable year of infection
   Before 2000 00 0
   2000-2007 40 50.6
   2008  36 45.6
   Data not available 03 3.8
Household income (US$)
  <150 59 74.7
  150-500 18 22.8
   >500 00 0
   Data not available 02 2.5
Number of dependants
   1-5  58 73.4
    ≥6 04 5.1
    Data not available 17 21.5
Highest level of education
   Not educated 02 2.5
   ≤Grade 5 04 5.1
   Grade 6 and above 63 79.7
   University 06 7.6
   Data not available 04 5.1 0.1
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Fig. 1. Phylogenetic analysis of partial HIV pol   
sequences from drug-naïve individuals 
from northeastern South Africa   
The tree was generated by the neigbhour-joining 
method and shows most test sequences (in bold 
face) clustering and intermingling with reference 
HIV-1 subtype C sequences previously obtained 
from northeastern South Africa. This shows that 
the majority of the test sequences are HIV-1 
subtype C sequences on the pol gene. One seq-
uence clusters with subtype B, and another is 
closely related to subtype J. The tree was rooted 
with an HIV-1 group O sequence. Five sequences 
were excluded from the phylogenetic analysis 
because of shorter lengths. 
has a mosaic structure and was related to CRF_11 
(Fig.  2).  The  STAR  genotyping  feature  with  the 
CRP analysis also assigned 08MB26ZA to CRF_11. 
Futhermore, this sample harboured the only D67G 
NRTI  mutation  observed  in  the  study.  Pure  sub-
types were assigned to all the other sequences after 
bootscanning analysis. The mean genetic distance 
for the PR sequences ranged from 0.0239 to 0.2519 
and 0.0273 to 0.1527 for the RT sequences. Con-
sidering the first 300 amino acids in the RT gene, Nwobegahay JM et al.
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sequence alignment showed that the consensus of 
the test viruses was identical to the global subtype 
C consensus. It differed from the global subtype B 
consensus at 18 positions (V35T, E36A, T39E, S48T, 
K122E,  D123G,  K173A,  D177E,  T200A,  Q207E, 
R211K,  V245Q,  A272P,  K277R,  T286A,  E291D, 
V292I, and I293V). Amino acid alignment of the 
PR gene showed that the test consensus was iden-
tical to the global subtype C consensus, except at 
position T13I. It differed from the global subtype 
B consensus at eight positions (T12S, I15V, L19I, 
M36I, R41K, H69K, L89M, and I93L).
Sequence accession numbers
The PR and RT gene sequences reported here have 
been submitted to GenBank with the following ac-
cession numbers: PR: GU188807-GU188752; RT: 
GU188753-GU188806.
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Fig. 2. Subtype assignment and HIV-1 subtype recombination analysis of 08MB26ZA
Panel A shows the subtype assignments of the partial pol based on phylogenetic analysis while 
panel B shows the recombinant proﬁle based on bootscanning analysis. The combined analysis 
shows that the isolate is an HIV-1 subtype J-like virus   
DISCUSSION
The development of drug resistance is an impor-
tant attribute of HIV. Infection with drug-resistant 
viruses complicates the clinical management of 
patients. Due to the emergence of resistant viruses, 
surveillance of drug-resistant variants among the 
population is necessary as this may inform the es-
tablishment of sentinel surveillance or genotypic 
resistance testing before the initiation of therapy 
(3,8,17,18). 
Antiretroviral treatment was started at the Mank-
weng community in 2004, four years before the 
collection of samples, within which time there is a 
possibility of emergence of resistance and transmis-
sion. Thus, the aim of the present study was to de-
termine the prevalence of drug resistance-associa- 
ted mutations in drug-naïve individuals in Mank-Nwobegahay JM et al. Antiretroviral drug resistance among drug-naïve persons
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weng, South Africa. The study participants were 
individuals who ‘walked’ into the HIV Voluntary 
Testing and Counselling Centre for the first time. 
Blood samples were collected sequentially from in-
dividuals who tested positive. Resistance-associated 
mutations were detected in five of the 54 analyzed 
subjects, giving a prevalence of patients with resist-
ant viruses of 9.3%. Only NRTI and PI resistance 
mutations were detected. According to the WHO 
resistance classification, a prevalence of 9.3% is   
moderately high (5-15%). Furthermore, the ob-
served prevalence was also relatively higher com-
pared to what has been previously reported from 
other parts of South Africa. For example, a surveil-
lance study of drug resistance mutations in naïve 
persons in Gauteng province in 2002 and 2004 
reported a 4.2% prevalence (9). In another study 
in Cape Town (Western Cape province), the preva-
lence of major drug resistance mutations in naïve 
patients was 2.5% (11). Similarly, a prevalence of 
3.6% has been reported from the Free state (19). 
Low levels (<5%) or the absence of drug resistance 
mutations have been reported in other southern 
African countries, such as Zambia (20) and Malawi 
(21). The prevalence observed in the present study 
is similar to what has been reported in some high-
income countries with more than a decade of ART-
use. Some of these countries include Britain, where 
a 14.2% resistance level (22) and the United States 
where up to 25% have been documented (23). Un-
like in high-income countries, the low prevalence 
of drug resistance mutations was expected in low-
income countries in the early phase of treatment 
roll-out because most patients were starting thera- 
py on highly-potent regimens. In high-income 
countries, ART-use began with resistance-associated 
monotherapy and one-class dual therapy (24). 
In the present study, all the observed resistance mu-
tations were detected in different individuals, with 
2008 being the probable year of infection. Muta-
tions in D67E, D67G, and T69D were detected in 
three women while T215Y and M46I were detected 
in two men. Several polymorphisms, such as K20R, 
M36I, and I93L, common in HIV-1 subtype C vi-
ruses and associated with drug resistance site, were 
also observed as has been previously reported (11). 
According to the WHO drug resistance algorithm, 
substitution D67E has the potential to cause low-
level resistance to zidovudine, stavudine, and dida-
nosine while D67G causes low-level resistance to 
zidovudine, and a potential for low-level resistance 
to abacavir, stavudine, and didanosine. In the same 
vein, T69D causes low-level resistance to didanos-
ine, with a potential for low-level resistance to sta-
vudine. Substitution T215Y causes intermediate re-
sistance to zidovudine and stavudine and low-level 
resistance to abacavir, didanosine, and tenofovir. 
The only protease inhibitor (PI) mutation observed 
—M46I—causes intermediate resistance to nelfi-
navir, with a potential for low-level resistance to 
ritonavir-boosted doses of atazanavir, fosamprena-
vir, indinavir, and lopinavir.  
At the time of the present study, a combination regi- 
men of stavudine, lamivudine, and efavirenz was 
the recommended first-line regimen, with nevirap-
ine replacing efavirenz for women of childbearing 
age. A PI-containing regimen was used for children 
aged less than three years and in second-line regi-
men for adults (8).
The study participants claimed not to have been 
treated with ARVs before the initiation of the study. 
Most study patients would benefit from the current 
first-line treatment regimen based on their viral 
genetic profiles. However, it is difficult to predict 
the spread of mutations observed and the impli-
cations on treatment outcomes at the population 
level. The resistance mutations described herein 
were observed after four years of the availability of 
treatment in the public health sector in the study 
area. It should also be noted that, although access 
to treatment in the public sector began in 2004, 
ARVs were available through the private sector be-
fore 2004, albeit at a higher cost and limited access. 
Accepting that the study participants had no prior 
exposure to ARVs, the mutations may have been 
acquired from transmitted viruses. Although the 
participants were apparently healthy, the absence 
of viral load and measurements of CD4 count do 
not allow a good estimation of their immunolog-
ic and virologic state. Mutations may revert over 
time in the absence of drug pressure, leading to a 
possible underestimation of transmitted resistance 
viruses. DNA amplification could not be obtained 
from about 25% of the samples probably because 
of very low viral loads, since most patients were 
asymptomatic. Subsequent surveillance studies are 
needed to confirm the findings of this report and 
to generate data relevant to sentinel surveillance 
policy and treatment-initiation guidelines. 
The identification of subtype C viruses as the pre-
dominant subtype is in agreement with findings 
of previous genotyping studies in northern South 
Africa (10,12). However, the presence of subtype 
B and CRF_11-related viruses has not been previ-
ously reported. Since only the partial pol gene of 
the CRF_11-like sample was analyzed, a full-length 
genomic analysis of the virus would be required to 
reveal its complete mosaic nature. 
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